Acceleron Pharma Inc

Acceleron Pharma — AHA Scientific Sessions 2020 Virtual

42 slides from Acceleron Pharma's conference presentation, Nov 13, 2020

  1. Slide 1: AHA 2020 Virtual: Updates from the PULSAR and SPECTRA Trials of Sotatercept in PAH

    Exhibit 99.3 AHA 2020 Virtual: Updates from the PULSAR and SPECTRA Trials of Sotatercept in PAH November 13, 2020 Sotatercept is an investigational therapy that is not approved for any use in any country.

  2. Slide 2: Forward-Looking Statements

    Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regarding the development and commercialization of sotatercept in pulmonary arterial hypertension (“PAH”) and of the Company’s oth

  3. Slide 3: Our Special Guest Presenters on Today's Call

    Our Special Guest Presenters on Today’s Call Vallerie McLaughlin, MD Aaron Waxman, MD, PhD Professor of Cardiovascular Medicine; Director, Pulmonary Vascular Disease Program, Director of the Pulmonary Hypertension Program, Brigham and Women’s Hospital; University of Michigan Associate Professor of M

  4. Slide 4: Habib Dable, Chief Executive Officer

    Habib Dable Chief Executive Officer This presentation is for investor relations purposes only – Not for product promotional purposes.

  5. Slide 5: Sotatercept: Significant Progress in 2020

    Sotatercept: Significant Progress in 2020 PRECLINICAL REGULATORY CLINICAL CLINICAL Upcoming Phase 3 Trial Starts Planned BREAKTHROUGH THERAPY DESIGNATION SCIENCE TRANSLATIONAL MEDICINE RESEARCH ARTICLE PRIME – PRIORITY MEDICINES This presentation is for investor relations purposes only – Not for pro

  6. Slide 6: Presentations at AHA Scientific Sessions 2020

    Presentations at AHA Scientific Sessions 2020 November 13-17, 2020  A virtual experience CLINICAL PRESENTATIONS • Sotatercept Improves Right Ventricular - Pulmonary Arterial Coupling and Right Ventricular Function in the PULSAR Study: A Phase 2, double-blind, placebo controlled, randomized study to

  7. Slide 7: Vallerie McLaughlin, MD

    Vallerie McLaughlin, MD Professor of Cardiovascular Medicine; Director of the Pulmonary Hypertension Program, University of Michigan Investigator in the PULSAR trial and a paid consultant to Acceleron 7 This presentation is for investor relations purposes only – Not for product promotional purposes.

  8. Slide 8: Sotatercept improves RV-PA coupling and RV function in the PULSAR study

    Sotatercept improves right ventricular – pulmonary arterial coupling and right ventricular function in the PULSAR study A Phase 2, double-blind, placebo controlled, randomized study to compare the efficacy and safety of sotatercept versus placebo when added to standard of care for the treatment of p

  9. Slide 9: Disclosures

    Disclosures Financial relationships with relevant commercial interests for three years preceding this presentation: Dr. McLaughlin reports grants and personal fees from Acceleron, Actelion, Bayer, Gossamer, and United Therapeutics; personal fees from Altavant, Caremark, CiVi Biopharma and Neuroderm

  10. Slide 10: Right ventricular dysfunction in PAH

    Right ventricular dysfunction in PAH • Right ventricular dysfunction is a central feature of PAH and the main factor affecting prognosis1 • Energy transfer between ventricle contractility and arterial afterload is termed coupling. Energy transfer specifically between the right ventricle (RV) and pul

  11. Slide 11: Echocardiographic estimation of RV-PA coupling

    Echocardiographic estimation of RV–PA coupling • RV–PA coupling can be estimated non-invasively as a ratio of TAPSE/PASP values* • A TAPSE/PASP ratio of ≥0.31 mm/mm Hg is associated with a better prognosis and reduced risk of clinical worsening1 PASP = TRV2 × 4 + RA pressure RV–PA coupling = TAPSE/P

  12. Slide 12: Sotatercept and the role of BMPR-II/TGF-β signaling

    Sotatercept and the role of BMPR-II/TGF-β signaling • Sotatercept is a novel, first-in-class fusion protein comprising the extracellular domain of human activin receptor type IIA linked to the Fc domain of human immunoglobulin G1 • Sotatercept is proposed to act by rebalancing signaling between pro-

  13. Slide 13: PULSAR study design

    PULSAR study design A Phase 2, randomized, double-blind, placebo-controlled study to compare the safety and efficacy of sotatercept versus placebo when added to standard of care (SOC) for the treatment of PAH in 106 patients at 43 sites across eight countries (NCT03496207) Inclusion criteria • WHO G

  14. Slide 14: PULSAR study design

    PULSAR study design A Phase 2, randomized, double-blind, placebo-controlled study to compare the safety and efficacy of sotatercept versus placebo when added to standard of care (SOC) for the treatment of PAH in 106 patients at 43 sites across eight countries (NCT03496207) Inclusion criteria Primary

  15. Slide 15: Methods

    Methods • Echocardiography was performed by the local lab at each site and centrally read • Calculation of RV-PA coupling is dependent on paired results for three parameters (TRV, RAP, TAPSE) at baseline and at Placebo + SOC (n=30) EOP† • Data analyses on the remaining patients is ongoing • Unavaila

  16. Slide 16: PULSAR study: Baseline characteristics (1/2)

    PULSAR study: Baseline characteristics (1/2) Sotatercept Sotatercept Placebo Total 0.3 mg/kg 0.7 mg/kg n=32 n=106 n=32 n=42 Female, n (%) 26 (81) 29 (91) 37 (88) 92 (87) Age, mean (range), years 46 (21–71) 48.5 (23–80) 48.5 (19–77) 48 (19–80) Time since diagnosis, mean (range), years 7.2 (0.3–22) 7.

  17. Slide 17: PULSAR study: Baseline characteristics (2/2)

    PULSAR study: Baseline characteristics (2/2) Sotatercept Sotatercept Placebo Total 0.3 mg/kg 0.7 mg/kg n=32 n=106 n=32 n=42 WHO functional class, n (%) II 17 (53) 15 (47) 24 (57) 56 (53) III 15 (47) 17 (53) 18 (43) 50 (47) Standard-of-care PAH therapy, n (%) Parenteral prostacyclin 10 (31) 11 (34) 1

  18. Slide 18: PULSAR results: Invasive hemodynamics

    PULSAR results: Invasive hemodynamics (n=102) Primary analysis data cut-off date 14 January 2020 Bar graphs represent mean ± standard deviation †EOP represents data obtained at the end of the placebo-controlled treatment period (24 weeks) CO: cardiac output; EOP: end of placebo-controlled treatment

  19. Slide 19: PULSAR results: Echocardiography

    PULSAR results: Echocardiography (n=94) Placebo + SOC Sotatercept 0.3 mg/kg + SOC Sotatercept 0.7 mg/kg + SOC LS mean difference LS mean difference Endpoint LS mean‡ LS mean P value LS mean P value (95% CI) (95% CI) RVEDA (cm2) −0.00 (0.68) −2.5 (0.66) −2.5 (−4.4, −0.55) 0.0122 −4.7 (0.61) −4.6 (−6.

  20. Slide 20: PULSAR results: Echocardiography

    PULSAR results: Echocardiography † Placebo + SOC Sotatercept 0.3 mg/kg + SOC Sotatercept 0.7 mg/kg + SOC LS mean difference LS mean difference Endpoint, n LS mean, n‡ LS mean, n P value LS mean, n P value (95% CI) (95% CI) PASP (mm Hg), 54 4.8 (4.1), 20 −24.3 (4.7), 16 −29.1 (−41.6, −16.6) <0.0001 −

  21. Slide 21: PULSAR results: RV-PA coupling

    PULSAR results: RV–PA coupling (n=51) 0.31 mm/mm Hg cut-off§ Placebo + SOC (n=19) Sotatercept 0.3 mg/kg + SOC (n=15) Sotatercept 0.7 mg/kg + SOC (n=17) Placebo + SOC Sotatercept 0.3 mg/kg + SOC Sotatercept 0.7 mg/kg + SOC LS mean difference LS mean difference Endpoint LS mean‡ LS mean P value LS mea

  22. Slide 22: Conclusions

    Conclusions • In this limited subgroup of the PULSAR study: o Treatment with sotatercept was associated with statistically significant improvements in RV–PA coupling and RV function when compared with placebo o Significant improvement from baseline to week 24 in both sotatercept dose groups versus p

  23. Slide 23: PULSAR study: Acknowledgements

    PULSAR study: Acknowledgements • We thank all the patients, their families, and all the PULSAR study investigators who participated in the trial – PULSAR study investigators: Y. Adir, H. Alnuaimat, M. Andrade-Lima, J. Arakaki, R. Argula, A. Baloira, D. Baratz, J. Barberá, A. Bar-Shai, C. Berastagui,

  24. Slide 24: Aaron Waxman, MD, PhD

    Aaron Waxman, MD, PhD Director, Pulmonary Vascular Disease Program, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School Principal investigator in the SPECTRA trial and a paid consultant to Acceleron 24 This presentation is for investor relations purposes only – Not

  25. Slide 25: SPECTRA and Beyond: Signs of Disease Modification?

    SPECTRA and Beyond: Signs of Disease Modification? Aaron B Waxman, MD, PhD Director, Pulmonary Vascular Disease Program Brigham and Women’s Hospital, Cardiovascular Medicine, Pulmonary and Critical Care #AHA20

  26. Slide 26: Disclosures

    Disclosures Financial relationships with relevant commercial interests for three years preceding this presentation: • Acceleron Pharma Sotatercept is an investigational product that is not approved for any use in any country 26

  27. Slide 27: Sotatercept and the role of BMPR-II/TGF-β signaling

    Sotatercept and the role of BMPR-II/TGF-β signaling • Sotatercept is a novel, first-in-class fusion protein comprising the extracellular domain of human activin receptor type IIA linked to the Fc domain of human immunoglobulin G1 • Sotatercept is proposed to act by rebalancing signaling between pro-

  28. Slide 28: SPECTRA study design

    SPECTRA study design A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study to Assess the Effects of Sotatercept for the Treatment of PAH in up to 25 patients at 4 sites across the USA • WHO PH Group I (PAH) Open-label treatment period Extension period Post-treatment follow-up • Idiopathic

  29. Slide 29: SPECTRA study: iCPET assessments

    SPECTRA study: iCPET assessments • Primary endpoint: Change from baseline in peak oxygen uptake (VO2 max) at 24 weeks • Secondary endpoints from iCPET measured as change from baseline at 24 weeks: • Ventilatory efficiency (VE/VCO2 slope) • Cardiac index (L/min/m2) • Mean pulmonary artery pressure, (

  30. Slide 30: How do we perform iCPET?

    How do we perform iCPET? 30 iCPET: invasive cardiopulmonary exercise testing; RA: right atrium; VO2: peak oxygen uptake

  31. Slide 31: SPECTRA study: Baseline characteristics

    SPECTRA study: Baseline characteristics Total N=10 Female, n 6 Age, median (range), years 45 (25-66) Time since diagnosis, median (range), years 3.2 (0.6-13.1) PAH classification, n Idiopathic 5 Associated with connective-tissue disease 4 Heritable 1 Standard-of-care PAH therapy, n Parenteral prosta

  32. Slide 32: SPECTRA study results: Supine Resting Hemodynamics

    SPECTRA study results: Supine Resting Hemodynamics Baseline Week 24/EOS# (n=10) (n=10) Mean Pulmonary Arterial Pressure (mPAP), mmHg 43.4 ± 9.7 30.6 ± 9.7 Pulmonary Arterial Wedge Pressure (PAWP), mmHg 10.0 ± 4.0 9.1 ± 4.8 Cardiac Output (CO), L/min 4.7 ± 0.7 4.8 ± 1.4 Pulmonary Vascular Resistance

  33. Slide 33: SPECTRA Study: Safety

    SPECTRA Study: Safety Treatment Emergent Adverse Events (TEAE) reported: • 9/10 patients reported at least one TEAE • Arthralgia, dizziness, fluid overload, gingival bleeding, hematochezia, hemoglobin increased, infusion site pain, palpitations, pyrexia, upper respiratory tract infection, weight inc

  34. Slide 34: SPECTRA Study: Case Report of First Patient (1/2)

    SPECTRA Study: Case Report of First Patient (1/2) • 25-year-old female, idiopathic PAH for 4.7 years, receiving tadalafil and ambrisentan for the treatment of PAH. At baseline, subject was classified as WHO FC III and 6MWD was 285.5 m. • The subject’s medical history includes gastroesophageal reflux

  35. Slide 35: SPECTRA Study Case Report of First Patient (2/2)

    SPECTRA Study Case Report of First Patient (2/2) Peak Exercise Hemodynamics (iCPET) Baseline Week 24 Week 48 Work, W 39 66 85 mPAP, mmHg 41 27 23 TPG, mmHg 37 25 22 PAWP, mmHg 4 2 1 CO, L/min 7.0 7.84 7.4 PVR, dynes-sec/cm5 423 255 237 Pulmonary artery compliance, mL/mmHg 2.2 3.9 2.3 VO2 max, mL/kg/

  36. Slide 36: Conclusions

    Conclusions • The ongoing SPECTRA study has shown substantial improvements in hemodynamics as well as exercise tolerance and capacity in the limited number of subjects studied to date. • Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH1. • Addit

  37. Slide 37: SPECTRA study: Acknowledgements

    SPECTRA study: Acknowledgements • We thank all the patients, their families, and all the SPECTRA study investigators who participated in the trial – SPECTRA study investigators: Aaron B. Waxman, MD, PhD, Franz Rischard, MD, Michael Risbano, MD, and Robert Frantz, MD. – The study was sponsored by Acc

  38. Slide 38: Summary | Jay T. Backstrom, MD, MPH

    Summary | Jay T. Backstrom, MD, MPH EVP, Head of Research & Development This presentation is for investor relations purposes only – Not for product promotional purposes.

  39. Slide 39: AHA 2020: Key Highlights from the Sotatercept Presentations

    AHA 2020: Key Highlights from the Sotatercept Presentations • Echo data received “Cardiopulmonary Best Abstract” • Sotatercept associated with measures of improved right ventricular function • Preliminary hemodynamic data consistent with PULSAR ― Reduction in PVR and mPAP ― Improvement in exercise t

  40. Slide 40: Upcoming Priorities for Sotatercept Program in PAH

    Upcoming Priorities for Sotatercept Program in PAH Initiation of STELLAR PULSAR open-label Additional results HYPERION Phase 3 (early Phase 3 trial planned extension study expected from the intervention) trial and for YE:2020 update expected in SPECTRA trial in ZENITH Phase 3 (later 1H:21 1H:21 inte

  41. Slide 41: Sotatercept Phase 3 Clinical Development Plan and Vision

    Sotatercept Phase 3 Clinical Development Plan and Vision REGISTRATIONAL LABEL EXPANSION SOTATERCEPT VISION BACKBONE THERAPY IN PAH Phase 3 Early Intervention Study Main Phase 3 Study ZENITH Phase 3 Later Intervention Study Sotatercept is an investigational therapy that is not approved for any use in

  42. Slide 42: Question & Answer Session

    Question & Answer Session Habib Dable Vallerie McLaughlin, MD* President & Chief Executive Officer Professor, Cardiovascular Medicine; Director, Pulmonary Hypertension Program, University of Michigan Jay T. Backstrom, MD, MPH EVP, Head of Research & Development Aaron Waxman, MD, PhD** Director, Pulm

Acceleron Pharma — AHA Scientific Sessions 2020 Virtual on 6ix